![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Effect of Baseline Resistance-Associated Variants on SVR With the 3D Regimen Plus RBV
|
|
|
Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
Mark Sulkowski1, Preethi Krishnan2, Rakesh Tripathi2, Gretja Schnell2, Yan Xie2, Daniel E Cohen2, Roger Trinh2, Nancy S Shulman2, Tami Pilot-Mati as2, Christi ne Collins2
1Viral Hepatitis Center, Johns Hopkins University, Baltimore, Maryland, United States; 2AbbVie Inc., North Chicago, Illinois, United States
![APASL1](../images/022416/022416-16/APASL1.gif)
![APASL2](../images/022416/022416-16/APASL2.gif)
![APASL3](../images/022416/022416-16/APASL3.gif)
![APASL4](../images/022416/022416-16/APASL4.gif)
![APASL5](../images/022416/022416-16/APASL5.gif)
![APASL6](../images/022416/022416-16/APASL6.gif)
![APASL7](../images/022416/022416-16/APASL7.gif)
![APASL8](../images/022416/022416-16/APASL8.gif)
![APASL9](../images/022416/022416-16/APASL9.gif)
![APASL10](../images/022416/022416-16/APASL10.gif)
![APASL11](../images/022416/022416-16/APASL11.gif)
![APASL12](../images/022416/022416-16/APASL12.gif)
![APASL13](../images/022416/022416-16/APASL13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|